Generate Biomedicines, Inc.

Generate Biomedicines, Inc. is a clinical-stage biotechnology company focused on using machine learning and generative biology to design novel protein therapeutics. The company’s Generate Platform combines computational design with biological engineering to create medicines across multiple protein-based modalities, including antibodies, enzymes, cytokines, peptides, and cell therapies. Its pipeline includes investigational programs such as GB-0895 for severe asthma, GB-4362, and GB-5267, reflecting its emphasis on developing treatments for complex and hard-to-address diseases. Based in Somerville, Massachusetts, Generate Biomedicines operates at the intersection of artificial intelligence, drug discovery, and therapeutic development, serving as a platform-driven innovator in modern biomedicine.

Sector

Healthcare

Industry

Biotechnology

CEO

Mr. Michael T. Nally M.B.A.

Employees

312

Headquarters

Somerville, MA, United States

Website

generatebiomedicines.com